The Anabolic Effect of Teriparatide is Undermined by Low Levels of High-Density Lipoprotein Cholesterol

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Calcified Tissue International

• Publication date

  2013-08-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00223-013-9772-0PMID 23907724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between vitamin D and cardiovascular disease predictors in overweight and obese Koreans

  2013cited by this paper
• PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells

  2011cited by this paper
• Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids

  2011cited by this paper
• Lipid Profiles and Bone Mineral Density in Pre- and Postmenopausal Women in Korea

  2010cited by this paper
• Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss.

  2009cited by this paper
• HDL3 reduces the association and modulates the metabolism of oxidized LDL by osteoblastic cells: A protection against cell death

  2008cited by this paper
• Hyperlipidemia Impairs Osteoanabolic Effects of PTH

  2008cited by this paper
• Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

  2008cited by this paper
• Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment

  2008cited by this paper
• Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

  2007cited by this paper
• Atherogenic Phospholipids Attenuate Osteogenic Signaling by BMP-2 and Parathyroid Hormone in Osteoblasts*

  2007cited by this paper
• Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis

  2007cited by this paper
• ApoE Gene Deficiency Enhances the Reduction of Bone Formation Induced by a High‐Fat Diet Through the Stimulation of p53‐Mediated Apoptosis in Osteoblastic Cells

  2007cited by this paper
• D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet Published, JLR Papers in Press, July 12, 2006.

  2006cited by this paper
• Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.

  2006cited by this paper
• D-4F and Statins Synergize to Render HDL Antiinflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein E–Null Mice

  2005cited by this paper
• PTH(1-34) Affects Osteoprotegerin Production in Human PDL Cells in vitro

  2005cited by this paper
• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

  2005cited by this paper
• Hyperlipidemia Promotes Osteoclastic Potential of Bone Marrow Cells Ex Vivo

  2004cited by this paper
• Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.

  2004cited by this paper
• Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment.

  2003cited by this paper
• The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

  2003cited by this paper
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

  2003cited by this paper
• The anabolic effects of parathyroid hormone therapy.

  2003cited by this paper
• The effects of recombinant human parathyroid hormone, rhPTH(1-84), on bone mass in undernourished rats.

  2002cited by this paper
• 8-Isoprostaglandin E2 Enhances Receptor-activated NFκB Ligand (RANKL)-dependent Osteoclastic Potential of Marrow Hematopoietic Precursors via the cAMP Pathway*

  2002cited by this paper
• Plasma lipids and osteoporosis in postmenopausal women.

  2002cited by this paper
• A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Oxidative stress modulates osteoblastic differentiation of vascular and bone cells.

  2001cited by this paper
• Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *

  2001cited by this paper
• Short-Term Increases in Bone Turnover Markers Predict Parathyroid Hormone-Induced Spinal Bone Mineral Density Gains in Postmenopausal Women with Glucocorticoid-Induced Osteoporosis

  2000cited by this paper
• Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.

  2000cited by this paper
• Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

  2000cited by this paper
• Atherogenic Diet and Minimally Oxidized Low Density Lipoprotein Inhibit Osteogenic and Promote Adipogenic Differentiation of Marrow Stromal Cells

  1999cited by this paper
• Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

  1998cited by this paper
• Parathyroid hormone (1-34) increased total body bone mass in aged female rats.

  1998cited by this paper
• Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients.

  1997cited by this paper
• The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture.

  1996cited by this paper
• Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit

  1985cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships

  2024cites this paper
• Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification

  2023cites this paper
• Lipids in the Bone Marrow: An Evolving Perspective.

  2020cites this paper
• A community-based study of the relationship between calcaneal bone mineral density and systemic parameters of blood glucose and lipids

  2019cites this paper
• Regulation of calcific vascular and valvular disease by nuclear receptors.

  2019cites this paper
• Preventive effects of Polygonum multiflorum on glucocorticoid-induced osteoporosis in rats

  2017cites this paper
• Internal Medicine: Open Access

  2014cites this paper
• Roles of Parathyroid Hormone (PTH) Receptor and Reactive Oxygen Species in Hyperlipidemia‐Induced PTH Resistance in Preosteoblasts

  2014cites this paper
• A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia

  2014cites this paper
• Effects of bioactive lipids and lipoproteins on bone.

  2014cites this paper
• Serum Lipids Effect on Bone Mineral Density: A Pilot Study in Apparently Healthy Syrians

  2014cites this paper